Vegetable compound could become ingredient to treating leukemia
HOUSTON -- (December 12, 2012) -- It looks like your mother was on to something when she said, “Eat your vegetables!”
A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine. The findings appear in the current edition of PLOS ONE.
"Acute lymphoblastic leukemia is a type of cancer of the white blood cells common in children," said Dr. Daniel Lacorazza, assistant professor of pathology & immunology. "There is about an 80 percent cure rate, but some children don’t respond to treatment. For those cases, we are in need of alternative treatments."
Lacorazza and his colleagues focused on purified sulforaphane, a natural compound found in broccoli believed to have both preventive and therapeutic properties in solid tumors. Studies have shown that people who eat a diet rich in cruciferous vegetables have a lower risk of some cancers.
"There have not been definitive studies showing how this compound interacts with blood cancers," Lacorazza said.
To study how this compound would act on acute lymphoblastic leukemia, researchers, led by Dr. Koramit Suppipat, lead author of the study who performed this work while a clinical fellow in the Texas Children’s Cancer and Hematology Centers, incubated human-derived leukemic cell lines and primary lymphoblasts from pediatric patients with the compound. The cancer cells died while the healthy cells obtained from healthy donors were unaffected. Studies tested in pre-clinical mouse models showed similar results.
Lacorazza said the compound works by entering the cells and reacting with certain proteins. More studies will be needed, but researchers believe this compound could one day be used as a treatment option in combination with current therapies. They also are working to determine which proteins are affected by sulforaphane and how. This could identify a new treatment target that might be affected by other types of cancer cells as well.
"Sulforaphane is a natural product. However, what we used in this study is a concentrated purified form," said Lacorazza. "So while eating cruciferous vegetables is good for you, it will not have the same effect as what we saw in the lab."
Others who contributed to the study include Chun Shik Park and Ye Shen, both with the department of pathology & immunology at BCM; and Xiao Zhu, with the Summer Medical and Research Training Program (SMART) at BCM. Lacorazza is also with the department of pediatrics, BCM. Suppipat is currently a clinical instructor in the department of medicine at King Chulalongkorn Memorial Hospital in Bangkok, Thailand.
Funding for this study came from The Gabrielle Angel Foundation for Cancer Research and the Alkek Award for Pilot Projects on Experimental Therapeutic at BCM.
Media Contact
Graciela Gutierrez
713-798-4710
ggutierr@bcm.edu
News Features
-
- May 14, 2013
- 'Off-the-shelf' virus-specific T-cells fight viral infections in stem cell transplant patients
Viral infections present deadly threats to patients who have received donor blood, marrow and cord stem cells transplants and are immune deficient while their transplants begin to work.
-
- April 9, 2013
- BCM major part of new pediatric cancer Dream Team initiative
Baylor College of Medicine is part of a Dream Team of childhood cancer researchers that will focus on melding the fields of genomics and immunotherapy to advance treatment for pediatric cancer.
-
- March 28, 2013
- Wipe Out Kids’ Cancer donates $75,000 to Texas Children’s Cancer Center
The grant will be used to fund a research project on neuroblastoma, an aggressive pediatric cancer that strikes approximately 650 children a year in the U.S., usually before age 5.
-
- March 1, 2013
- Fundraiser supports pediatric cancer in South Texas
Actor Diego Boneta, top right, helped raised $90,000 for the Vannie Cook Children’s Cancer Clinic in South Texas at the 2013 Radiothon.
-
- February 27, 2013
- Hematology-oncology faculty members receive renewed NIH funding to enhance T cell therapy for cancer
Hematology-oncology faculty members from the Center for Cell and Gene Therapy (CAGT) have received a $11.3 million renewal grant from the National Institutes of Health to advance the development of more effective and less toxic targeted T cell therapies for children and adults with cancer.
-
- February 1, 2013
- Grant funds developmental therapeutics program
A five-year, $1.75 million grant from Alex’s Lemonade Stand Foundation was awarded to Texas Children’s Cancer Center to establish the Developmental Therapeutics Center of Excellence.
-
- January 4, 2013
- Houston Radio Host Kevin Kline Completes his 62,000 Step Stair Run
Kevin Kline, Houston morning radio host on The New 93Q, ran 62,000 Stairs at Constellation Field, home of the Sugar Land Skeeters Baseball team in Sugarland, TX.
- December 12, 2012
- Vegetable compound could become ingredient to treating leukemia
A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine. The findings appear in the current edition of PLOS ONE.
-
- December 11, 2012
- Montblanc and Texas Children’s Cancer Center encourage families to give a gift that counts this holiday season
Montblanc and Texas Children’s Cancer Center have launched a new initiative allowing people across the United States to show their support for children and adolescents fighting cancer by providing an opportunity to purchase a specially designed bracelet to be given to the parent of a pediatric cancer patient this holiday season.
-
- December 6, 2012
- Q&A: Sharon Plon on Baylor College of Medicine's First Year of Clinical Exome Sequencing
As a member of Baylor College of Medicine's Whole Genome Laboratory management committee, Sharon Plon has been a leader in establishing Baylor's clinical exome sequencing diagnostic test, which was launched last November.
This is part one of a two-part interview. Part two will appear in next week's issue.